Novartis Ag (NVS) Change in Acquisitions & Divestments (2009 - 2026)

Novartis Ag's (NVS) quarterly Change in Acquisitions & Divestments came in at -$3.0 million in Q1 2026, little changed year-on-year from -$3.0 million in Q1 2025, and up 78.57% quarter-over-quarter from -$14.0 million in Q4 2025.

Novartis Ag (NVS) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends

Novartis Ag has disclosed Change in Acquisitions & Divestments across 9 years of filings, most recently posting -$3.0 million for Q1 2026.

  • Change in Acquisitions & Divestments for Q1 2026 came in at -$3.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $143.0 million (down 83.56% YoY), and the FY2025 annual result was -$24.0 million, down 242.86% from the prior year.
  • Change in Acquisitions & Divestments came in at -$3.0 million for Q1 2026 at Novartis Ag, up from -$14.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $647.0 million in Q2 2024 to a low of -$14.0 million in Q4 2025.
  • The 5-year median for Change in Acquisitions & Divestments is $55.0 million (2023), against an average of $97.4 million.
  • Across the five-year window, Change in Acquisitions & Divestments jumped 1276.6% in 2024 and sank 104.76% in 2025, its largest moves.
  • Novartis Ag's Change in Acquisitions & Divestments stood at $12.0 million in 2022, then surged by 1125.0% to $147.0 million in 2023, then surged by 53.74% to $226.0 million in 2024, then slumped by 106.19% to -$14.0 million in 2025, then jumped by 78.57% to -$3.0 million in 2026.
  • The last three Change in Acquisitions & Divestments figures came in at -$3.0 million (Q1 2026), -$14.0 million (Q4 2025), and $140.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.00 Mn
Mar 31, 2026 -3.00 Mn
Dec 31, 2025 -14.00 Mn
Dec 31, 2025 -14.00 Mn
Sep 30, 2025 140.00 Mn
Sep 30, 2025 140.00 Mn
Jun 30, 2025 20.00 Mn
Jun 30, 2025 20.00 Mn
Mar 31, 2025 -3.00 Mn
Mar 31, 2025 -3.00 Mn
Sep 30, 2024 226.00 Mn
Sep 30, 2024 226.00 Mn
Jun 30, 2024 647.00 Mn
Jun 30, 2024 647.00 Mn
Mar 31, 2024 63.00 Mn
Mar 31, 2024 63.00 Mn
Dec 31, 2023 147.00 Mn
Dec 31, 2023 147.00 Mn
Sep 30, 2023 91.00 Mn
Sep 30, 2023 91.00 Mn